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Summary.-In 3 years, 118 patients with Hodgkin's disease have completed chemo-
therapy with chlorambucil, vinblastine, procarbazine and prednisolone (ChlVPP).
The complete remission rates were 90% for 29 patients previously treated with
radiotherapy, 67% for 73 patients previously untreated and 44% for 16 patients with
prior chemotherapy.
The 3-year survival rates for the first 70 patients in the series were 83% for pre-
viously irradiated patients, 84% for previously untreated patients and 67% for those
with prior chemotherapy. Forty-seven previously untreated or previously irradiated
patients in this group achieved complete remission. The 3-year disease-free survival
rates for these patients were 710% and 67% respectively.
This regimen gives complete remission and survival rates comparable with results
obtained with combinations including nitrogen mustard, while producing fewer side-
effects.
IN 1975, we introduced the ChlVPP
combination (chlorambucil, vinblastine,
prednisolone and procarbazine) for the
treatment of Hodgkin's disease. By re-
placing mustine (HN2) with chlorambucil,
our aim was to provide treatment which
was as effective as the original MOPP and
MVPP combinations (De Vita et al., 1970;
McElwain et al., 1973), but would avoid
the nausea and vomiting associated with
HN2 administration.
The remission rates for the first 70
patients treated with Ch]VPP were equiva-
lenttothose obtained withHN2-containing
combinations (McElwain et al., 1977).
We now present data for remission rates
in 118 patients, who completed treatment
between July 1975 and December 1977.
Three-year survival data are now available
for the first 70 patients in the series, and
these form the basis of the second part of
this report.
*Present address: Department ofMedical Oncology,
Requests for reprints: Dr T. J. McElwain.
PATIENTS AND METHODS
Of118 patients, 79 were maleand39female.
The mean age was 29-5 years (range 3-76).
Seventy-three patients were previously un-
treated, 29 had relapsed after prior radio-
therapy, and 16 had relapsed after prior
chemotherapy (with orwithoutradiotherapy).
Details of patients according to previous
treatment are shown in Table I.
The Ann Arbor Staging Classification
(Carbone et al., 1971) was used. Seventy-five
patients were pathologically staged by
laparotomy (Gazet, 1973) and 43 were staged
clinically (McElwain et at., 1973). Among the
pathologically staged patients, 17 were
Stage II, 40 were Stage III and 18 were
Stage IV. Of those clinically staged, there
were 2 Stage 1, 13 Stage II? 9 Stage III and
19 Stage IV.
Histological classification was by the
criteria of Lukes & Butler (1966). Seventy-
two patients (61%) had nodular-sclerosing
Hodgkin's disease, ofwhom 39 were male and
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33 female. Thirty patients (25%) had mixed-
cellularity disease (26 male and 4 female).
Nine patients (8%, all male) had lymphocyte-
predominant disease, while 7 cases (6%) had
lymphocyte-depleted histology (5 males and
2 females).
Treatment
The drug combination is as follows:-
Days 1 to 14 (inclusive), orally.-Chlorambucil
6 mg/m2/day (> 10 mg/day). Procarbazine
100 mg/m2/day. Prednisolone 40 mg/day (ap-
propriate reduction for children).
Days 1and8, i.v.-Vinblastine6 mg/m2/day
(single dose >-10 mg).
The next course begins on Day 28, i.e. there
is a 2-week gap between courses.
The number of courses is determined by
the rate of response, as previously described
(McElwain et al., 1977).
In 42/73 previously untreated patients,
ChlVPP formed the first part of a combined
chemotherapy-radiotherapy protocol.
Thefullrationale ofthis combinedmodality
approach is given elsewhere (Peckham &
McElwain, 1977). In essence, the patients are
a group in whom by conventional criteria
radiotherapy is indicated as primary treat-
ment, but in whom cure with radiotherapy is
infrequent (Peckham et al., 1975). Our aim
has been to improve the survival of these
patients by treating them first with combina-
tion chemotherapy, and then, when remission
has been achieved, to give the radiotherapy
thatwould normally beindicated, for example
"mantle" radiotherapy for patients with
above-diaphragm Stage II disease or "total
nodal" radiotherapy for those with Stage III
disease.
Patients in this group included:
(a)
(b)
(c)
(d)
(e)
3 with lymphocyte-depleted histology.
8 with bulky mediastinal Stage II
disease.
11 with Stage II disease involving 3 or
more nodal areas above the diaphragm.
12 with Stage IIIA disease with an
involved spleen.
8 with Stage IIIB disease, who re-
ceived total nodal radiation after re-
mission with chemotherapy had been
achieved.
Adult patients with Stage IV and children
with Stage III and IV disease received
chemotherapy alone. No patient received
maintenance chemotherapy.
RESULTS
Remission rates
Complete remission was defined as
complete disappearance of the features of
Hodgkin's disease, clinically, radiologically
and biochemically.
The overall complete remission rate was
70%, which is comparable to that obtained
with both MOPP and MVPP. Detailed
rates according to previous treatment are
given in Table I. The highest rate (90%)
was seen in previously irradiated patients,
in agreement with the findings when
MVPP was used. (McElwain et al., 1973;
Sutcliffe et al., 1978).
The lowest rate (44%) for patients re-
lapsing after prior chemotherapy is similar
to that obtained with MVPP, and con-
firms that this is a group of patients with
advanced and progressive disease.
Remission rates according to age, sex,
presence ofsymptoms, histology and stage
are given in Table II. There was no signi-
ficant different in response attributable to
any of these features. The apparently
better results in Stage III patients than in
other stages is due to the greater number
of previously irradiated patients with this
stage of disease. These patients, although
initially classified as Stage III, had fre-
quently relapsed in only a few sites at the
beginningoftreatmentwithchemotherapy.
Survival ratesfor thefirst 70patients
The maximum follow-up on the 70
patients who formed the basis ofthe earlier
report is now 46 months. Overall and
disease-free survival rates for this group
were measured from the date of starting
chemotherapy, and were calculated by
means of life-table analysis.
Twenty patients in the first 70 received
elective radiotherapy in addition to
ChlVPP as part ofthe combined-modality
programme, and 23 patients received addi-
tional chemotherapy and/or radiotherapy
because of progressive disease or later
relapse. Twenty-seven patients had no
additional treatment.
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TABLE I.-Hodgkin's disease: distribution of patients according to previous treatment
No. of patients
7:3
29
PCT 4-RT
TOTAL
16
118
MIale
56
(77)
12
(41)
11
(69)
79
(67)
Females
17
(23)
17
(59)
5
(31)
:39
(33)
Alean age
in years
(median)
28
(26)
34
(32 5)
27 :3
(27.5)
29 5
(28 *7)
No. entering
complete
remission
(0/ )
49
(67)
26
(90)
7
(44)
82
(70)
AMean no.
of courses
to achieve
Iremnission
'3 *2
2-1
3-6
NPT No previous treatment.
PRT Previous radiotherapy.
PCT±RT Previous chemotherapy±radiotherapy.
TABLE II. Hodgkin's disea
rate according to age, pres
toms, histology and stage.
acd
No. of co]
patients rler
Age in years
<40
>40
Sex
94
24
Al 79
F 39
Symptoms
A 67
B 51
Histology
LP 9
NS 72
Me 30
LD 7
Stage
IA 2
IIA 15
IIB 15
IIIA 33
IIIB 16
IVA 17
IVB 20
Total 118
LP Lymphocyte-predominant.
NS Nodular sclerosis.
MC Mixed cellularity.
LD Lymphocyte-depleted.
zse: remission inferiorsurvivalrate (67%)ofpatientswho
ence of symp- had received prior chemotherapy accords
with their lower remission rates, and agrees
No. with the finding,s of previous studies.
levtig
A total of 53/70 patients achieved com-
missiorl 0// plete remission, and their relapse-free
survival is shown in Fig. 2. In this group,
68 528 the predicted 3-year disease-free survival
rates for the 47 previously irradiated or
54 68 previously untreated patients who
28 72 achieved remission were 71% and 670%
respectively. These agree with results with
33 65 MVPP, where the corresponding rates
were 7700 and 64% (McElwain et al.,
4 44 1973). No patient who had previously
52 72 received chemotherapy has yet achieved
22 73 a disease-free survival of 3 years.
()
8
29
13
10
12
82
50
60
53
88
81
59
60
70
Overall survival rates according to
previous treatment are shown in Fig. l.
For patients previously untreated and
those previously irradiated, the 3-year
survival rates of 840o and 830o respec-
tively are very similar to those obtained
with both MOPP and MVPP. The slightly
Combined-modality programme
The 3-year survival of the patients
receiving elective radiotherapy after
ChlVPP is 100% and their 3-year disease-
free rate is 79o0 (Figs. 3 & 4). These results
compare favourably with overall and
disease-free survivals of 8300 and 71J
respectively which were achieved by the
patients receiving ChlVPP after relapse
from primary treatment with radiotherapv
(Figs. & 2). Clearly, elective combined-
modality treatment is an effective way of
increasing the survival of a group of
patients whose prognosis after radio-
therapy alone is poor, and giving the
chemotherapy before the radiotherapy is a
safe and convenient way of doing this.
NPT
PRT
170THREE YEARS WITH ChlVPP 171
1Wu
% 80
-6 60
E
t,, 40
a,)
._ 20
a
I-------&-----w-
_ ~~~~~~~~~~~20 12 'l1 -T -l T
-.. .* - -
------------- rr
7
U
4 8 12 16 20 24 28 32 36 40 44 48
Months
FIG. 1.-Hodgkin's disease: overall survival according to previous treatment offirst 70 patients in the
series (actual numbers given). no previous treatment (36); --- previous radiotherapy
(22); * previous chemotherapy ± radiotherapy (12).
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FIG. 2.-Hodgkin's disease: disease-free survival of the complete remitters in the first 70 patients in
the series (actual numbers given). - previous radiotherapy (21); no previous treat-
ment (26); previous chemotherapy ± radiotherapy (6).
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FIG. 3.- Hodgkin's disease: overall survival ofpreviously untreated patients according to subsequent
treatment (actual numbers given). elective radiotherapy (20); --- no elective radio-
therapy (16).
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FIG. 4.-Hodgkin's disease: disease-free survival of previously untreated patients according to
subsequent treatment (actual numbers given). elective radiotherapy (16); ---no
elective radiotherapy (10).
Previously untreated patients receiving
chemotherapy
For the 16 previously untreated patients
who did not receive radiotherapy after
ChlVPP, the overall and disease-free
survival rates at 3 years were 68% and
60% (Figs. 3 & 4). This is comparable to
those with other combinations.
Factors influencing survival
Comparative analysis of survival data
according to the following prognostic
factors has been done by the Mantel pro-
cedure (Mantel, 1963) with appropriate
adjustments for continuity:
(a) Remission status.-A total of 50
patients were in complete remission 12
months after the start of chemotherapy,
while 20 had evidence of active Hodgkin's
disease. The 3-year overall survival rates
of the 2 groups are 92% and 55% respec-
tively, as shown in Fig. 5. Excluding the
12 patients previously given chemo-
therapy, the difference between these 2
groups remains significant (P-0-01) and
this confirms the prognostic importance of
complete remission reported by Sutcliffe
et al. (1978).
(b) Age, sex, histology and stage.-An
analysis of the significance of these
variables is shown in Table III. The 12
patients treated with ChlVPP who had
TABLEIII.-Hodgkin's disease: analysis of
prognostic variables on thefirst 58patients
in the series (excluding 12 patients with
prior chemotherapy)
Disease-
Overall
3-year No.
No. of survival achieving
patients (%) remission
Age in years
<40
>40
Histology
LP
NS
MC
LD
Sex
M
F
Stage
<IIIA
IIIA
IIIB
VIA and B
Total
free
3-year
survival
of
complete
remitters
(%)
45 95 38 70
13 49 9 59
4
34
18
2
80
83
*
2
32
13
0
*
61
84
*
40 80 32 67
18 88 15 70
14
24
7
13
58
71
87
*
100
82
8
22
6
11
47
80
80
67
Stage <IIIA includes stages I and II, A and B.
* Numbers too small foradequate 3-yearfollow-up.
prior chemotherapy have been excluded,
as they represent a selected group of poor-
prognosis patients.
No significant differences in overall
survival due to sex, histology or stage
were apparent, though in several cases the
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FiG. 5.-Hodgkin's disease: overall survival according to remission status at one year after start of
treatment (first 70 patients in series; actual numbers given). in remission at one year (50);
not in remission at one year (20).
numbers were too small for meaningful
analysis. Overall survival was, however,
related to age, with those patients aged
over 40 faring significantly worse than
under 40 (P=0.001). Higher death rates
among older patients with Hodgkin's
disease have previously been noted by
Nixon & Aisenberg (1974) and Sutcliffe et
al. (1978).
With regard to disease-free survival, no
significant difference in outcome could so
far be attributed to age, sex, histology or
stage of disease in patients receiving
Ch1VPP.
Drug toxicity
ChlVPP continues to be extremely well
tolerated. Side-effects have been relatively
minor, and the treatment can safely be
given to outpatients.
Ofthe 118 patients in this series, a total
of 11 experienced some degree of nausea
or vomiting after the first injection of
vinblastine, but this generally improved
with subsequent doses. Twenty-two
patients complained of occasional nausea,
and a further 2 developed skin rashes,
both symptoms being attributed to pro-
carbazine. Steroid-induced acne developed
in 3 patients, and 7 noticed slight loss of
hair. A mild vinblastine-induced neuro-
pathy, manifest by paraesthesiae, de-
veloped in 11 patients, but was not a major
problem. One patient developed steroid
myopathy which resolved after completion
of treatment. Routine prophylactic anti-
emetics were not given.
Asnotedin ourearlierreport onChlVPP,
marrow suppression has rarely been sig-
nificant. A delay in the start of treatment
has been necessary for 18 patients (usually
for one week) when the white blood cells
have fallen below 3000/mm3 or the plate-
lets below 80,000. Dose reductions due to
marrow toxicity have only been necessary
on a few occasions, and the actual dose of
each drug given continues to be over 95%
of the prescribed amount. On 3 occasions,
vincristine was substituted for vinblastine
when myelosuppression persisted.
Two patients have died of infection.
One, previously reported, was a 3-year-old
child who died of a Pneumocystis carinji
pneumonia while his Hodgkin's disease
was in partial remission. The second was a
67-year-old man who died of broncho-
pneumonia associated with disseminated
herpes zoster one month after completing
treatment. He was in complete remission
at the time of death.
One second malignancy has been seen.
The patient was a 57-year-old man who
developed acute myelomonocytic leukae-
mia one month after he had received 6
courses of Ch1VPP followed by a short
course ofirradiation.
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DISCUSSION
The results of treatment of the whole
groupof 118patientswith ChIVPP confirm
earlier experience with the combination.
It is well tolerated and produces an over-
all remission rate of 70%, comparable to
that obtained with more toxic mustine-
containing combinations. Moreover, there
is no difference between treatment with
MOPP or MVPP in the time taken to
achieve remission.
The survival obtained with ChIVPP,
both overall and disease-free, also agrees
with that produced by MVPP. It should
be noted, however, that in the MVPP
study additional maintenance chemo-
therapy wasgiven to allpatientsachieving
remission, while in the ChIVPP series sub-
sequent elective radiotherapy has been
used in the management of 42 patients.
Hence, the preliminary results are com-
parable with those obtained with other
combined-modality programmes (Rosen-
berg & Kaplan, 1975). In due course,
evaluation will include anappraisal ofany
long-term harmful effects, since Cannelos
et al. (1975) have already shown that the
second malignancy rate among patients
successfully treated for Hodgkin's disease
is significantly higher when radiotherapy
and chemotherapy have been combined.
As far as the group of 16 previously
untreated patients who received chemo-
therapy alone is concerned, the numbers
are notlargeenough for us to draw definite
conclusions, but so far their remission rate
and survival is good enough for us to
continue with ChIVPP until we have
information ongreaternumbers andlonger
follow-up.
In conclusion, ChIVPP provides effec-
tive chemotherapy with few side-effects
forpatients withHodgkin's disease, and is-
particularly suitable for those subse-
quently receiving irradiation. The results
to date are as good as those obtained witb
more toxic combinations.
We are grateful to Mr G. Tomkins of the South
Thames Cancer Registry for help with statistics.
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